Dr Dicky Abraham, Executive Director/Distinguished Scientist, Merck, United States
Prof Jeffrey Almond, Former Vice President Discovery Research and Development, Sanofi and Visiting Professor, University of Oxford - Oxford Vaccine Group, United Kingdom
Dr Annaliesa Anderson, Vice President and CSO Bacterial Vaccines, Pfizer, United States
Dr Jean-Christophe Audonnet, Senior Director, Research Strategy and Key Alliances, Bio R&D and Coordinatior at ZAPI, Merial, France
Dr Joeri Auwerx, Director, Discovery Research, ViroVet N.V., Belgium
Dr Lorne Babiuk, Former Vice President Research, University of Alberta, Canada
Dr Frank Baehner, Area Head Prophylactic Vaccines, CureVac, Germany
Dr Carl Barrett, Vice President of Translational Sciences, AstraZeneca Pharmaceuticals, United States
Dr Philip Beer, Physician Scientist and Precision Oncology Specialist, Sanger Institute, United Kingdom
Professor Fernando M. A. Bernardo, Chief of Veterinary Office, Portugal, DGAV, The Portuguese National Authority for Animal Health, Portugal
Dr Todd Black, Executive Director, Infectious Diseases, MSD, United States
Prof Marc Bonten, Professor, UMC Utrecht, Netherlands
Dr Maximilian Bosch, Medical Scientific Director, Pantec Biosolutions, Liechtenstein
Prof Anne Botteaux, Molecular Bacteriology Laboratory, Universite Libre De Bruxelles, Belgium
Dr Anissa Boumlic-Courtade, Vaccine Market Lead, EMEA, MERCK, France
Dr Helen Bright, Director, Flu Biopharm Development, MedImmune, United Kingdom
Dr Kate Broderick, Vice President, Research and Development, Inovio Pharmaceuticals, United States
Adam Buckley, VP Business Development, VBI Vaccines, United States
Dr Rosario Bullido, Head of Vet Inmuno Medicines Assessment Unit, Aemps, Spain
Dr Miles Carroll, Deputy Director, Public Health England, United Kingdom
Dr Senyon Choe, President of Mogam Institute for Biomedical Research & Professor, U.C.S.D., United States
Ashok Chopra, Distingushed Professor, University of Texas Medical Branch, United States
Prof Dennis Christensen, Head of Vaccine Adjuvant Research grp., Dept. Infectious Disease Immunology, Statens Serum Institute - Denmark, Denmark
Dr Chris Clarke, Global Medical Affairs Director, GSK Vaccines, Belgium
Dr Ralf Clemens, SVP, Grid Rio, Germany
Dr Jeffrey Cohen, Chief of Laboratory of Infectious Diseases, NIH, United States
Professor Louise Cosby, Head of Virology, Agri-Food and Biosciences Institute, United Kingdom
Marc Andre D Aoust, Vice President of Research and Innovation, Medicago, Canada
Prof Ron Dagan, head, pediatric Infectious diseases, Ben Gurion University, Israel
Morena D'Alise, Lead Immunologist, Nouscom, Italy
Michel De Baar, Executive Director BD & Licensing Europe, MSD, United Kingdom
Dr Isabel de la Mata, Principal Advisor for Health and Crisis management, European Commission, Belgium
Dr Evelyna Derhovanessian, Senior Scientist, BioNTech Ag, Germany
Dr Dimitri Diavatopoulos, Department of Pediatrics/ Laboratory of Pediatric Infectious Diseases (LPID), Radboud Center for Infectious Diseases, Netherlands
Dr Thomas G. Evans, Vaccitech, United Kingdom
Dr Ali Fattom, Sr. VP of Vaccines Research and Development, BlueWillow Biologics, United States
Dr Martin Friede, Coordinator, Initiative for Vaccine Research Immunization, Vaccines and Biologicals Department, WHO, Switzerland
Roman Galetto, Group Lead, Preclinical Manager, Cellectis Therapeutics, France
Kirsty Gapp, Global Business Manager Transdermal and Microneedle Drug Delivery, 3M, United Kingdom
Christiane Gerke, Head of Vaccine Programs, Institut Pasteur, France
Dr Arin Ghasparian, CEO, Virometix AG, Switzerland
Sarah Gilbert, Professor of Vaccinology, University of Oxford, United Kingdom
Dr David Gilham, Vice President of Research and Development, Celyad, Belgium
Dr Gregory Glenn, President, Research and Development, Novavax, United States
Cori Gorman, Vice President Of Precision Medicine & Manufacturing, Agenus, unknown
Dr Farshad Guirakhoo, CSO, GeoVax, Inc., United States
Professor Carlos A. Guzman, Head of the Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research (HZI), Germany
Dr Bassam Hallis, Head of Pre Clinical Development and General Project Manager, Public Health England, United Kingdom
Prof Mark Hatherill, Professor, S.A. Tuberculosis Vaccine Initiative, South Africa
Professor John Hayball, Professor, University of South Australia, Australia
Professor Peter Heegaard, Professor, National Veterinary Institute Technical University of Denmark, Denmark
Ana Maria Henao Restrepo, Implementation Research and Economic Analysis, Initiative for Vaccine Research, World Health Organisation, Switzerland
Dr Hanjo Hennemann, Chief Scientific Officer and Co Founder, VEROVACCiNES, Germany
David Hipkiss, Chief Executive Officer, Enesi Pharma Limited, United Kingdom
Dr Tim Hirst, CEO, GPN Vaccines, Australia
Dr Karin Hoelzer, Senior Officer, The Pew Charitable Trusts, United States
Dr Mark Howarth, Professor, University of Oxford, United Kingdom
Professor Dirk Jager, Managing Director, University Hospital of Heidelberg, Germany
Konrad Janik, Acting Medical Manager, Institute of Sera Biotechnology & Vaccines BIOMED, Poland
Dr Jan Jezek, Chief Scientific Officer, Arecor Ltd, United Kingdom
Professor Gregers Jungersen, Professor of Veterinary Immunology and Vaccinology, Technical University of Denmark, Denmark
Professor Lana Kandalaft, Director, Center of Experimental Therapeutics, University of Lausanne, Switzerland
Dr Maria Karasarides, Executive Director, ImmunoOncology, Regeneron Pharmaceuticals, United States
Paula Kinnunen, Research Director, Food Safety Authority Evira, Finland
Dr Olivier Kitten, Chief Executive Officer, Affilogic, France
Dr Elizabeth Klemm, Project Officer, Wellcome Trust, United Kingdom
Dr Wayne Koff, President and CEO, The Human Vaccines Project, United States
Dr Alexander Kort, SVP Corporate Development, Themis Bioscience GmbH, Austria
Professor Jeroen Kortekaas, Wageningen University, Netherlands
Greg Kulnis, Business Development Director, Covance, United States
Carlos Pinero Lambea, Researcher, Centre for Genomic Regulation, Spain
Dr Yotam Levin, Chief Executive Officer, NanoPass Technologies, Israel
Maria Lluch Senar, Co-Cordinator, Centre for Genomic Regulation, Spain
Dr Stephen Lockhart, Vice President and Head of Europe and Asia-Pacific Vaccine Clinical Research and Development (VCRD), Pfizer, United Kingdom
Dr Patricia Londono-Hayes, Sr. Director / Head R&D Initiatives, Europe, Sanofi, France
Alfred Luitjens, Director Cell Technology at Batavia Biosciences, Batavia Biosciences, Netherlands
Dr Anthony Simon Lynch, Senior Scientific Director, Janssen R&D, Netherlands
Pedro Madureira, CSO, Immunethep, Portugal
Dr Michael Makanga, Executive Director, European and Developing Countries Clinical Trials Partnership, Netherlands
Dr Anna-Karin Maltais, Chief Scientific Officer, Eurocine Vaccines AB, Sweden
Dr Michael Manns, Professor, Hannover Medical School, Germany
Dr Victor Mbao, Senior Program Specialist, International Development Research Centre, Kenya
Dr Douglas Mcneel, Chief Scientific Founder and Head of M.V.I. Scientific Advisory Board, Madison Vaccines Inc., United States
Professor Helen Mcshane, Professor Of Vaccinology Wellcome Senior Fellow PI Head Of TB Vaccines Group, The Jenner Institute - University of Oxford, United Kingdom
Dr Kees Melief, Chief Scientific Officer, I.S.A. Pharmaceuticals, Netherlands
Dr Maria Mellado, Application Specialist, Puritifcation Technologies, Sartorius Stedim Biotech, Spain
Prof Kingston Mills, Professor of Experimental Immunology, Trinity College Dublin, Ireland
Prof Emanuele Montomoli, Prof in Public Health University of Siena & CSO, VisMederi, Italy
Dr Geert Mudde, Chief Scientific Officer and Founder, OncoQR ML, Austria
Dr Tarit Mukhopadhyay, Senior Lecturer of Vaccine Bioprocess Development, University College London, United Kingdom
Dr Mel Munro, Project Manager, Biologicals Regulatory Affairs, Triveritas Limited, United Kingdom
Imraan Munshi, Global Communications Lead, Vaccines, MSD, United States
Andreas Neubert, Vice President Vaccines, IDT Biologika, Germany
Claire Nguyen Le, Exec Director, Clinical Development, Syneos Health, France
Dr Mikkel Nissum, Technical Development Leader, GSK Vaccine, Italy
Lord Jim O'Neill, Honorary Professor of Economics at the University of Manchester & author of AMR review UK, The University of Manchester, United Kingdom
Prof Ab Osterhaus, Director, Research Center for Emerging Infections and Zoonoses (RIZ), University of Veterinary Medicine Hannover, Netherlands
Prof Ab Osterhaus, Director, Research Center for Emerging Infections and Zoonoses (RIZ), University of Veterinary Medicine Hannover, Netherlands
Dr Arto Palmu, Research manager, head of Clinical Research Team, Public Health Evaluation and Projection Unit, Department of Public Health Solu, Finnish National Institute for Health and Welfare, Finland
Dr Cristina Peixoto, Head of Downstream Process A.C.T.U., iBET – Instituto de Biologia Experimental e Tecnológica, Portugal
Yoav Peretz, Global Scientific Director, Flow Cytometry, Covance, Canada
Dr Gregory Poland, Director of Mayo Vaccine Research Group, Mayo Clinic and Foundation, United States
Dr Jan Poolman, Head Bacterial Vaccine Discovery and Early Development, Janssen, Netherlands
Andrew Potter, CEO, VIDO-InterVac, Canada
Geert Preuveneers, Head of Regulatory Affairs Europe, MSD, Belgium
Prof Roman Prymula, Professor Preventive Medicine, Charles University in Prague, Czech Republic
Dr Ahmadur Rahman, Senior Clinical Director Oncology, MSD, United Kingdom
Dr Rino Rappuoli, Chief Scientist, GSK Vaccines, United States
Prof Robert Read, Head of Academic Unit - Clinical and Experimental Sciences, Professor of Infectious Diseases, Honorary Consultant Physician, University of Southampton, United Kingdom
Dr Merlin Robb, Deputy Director MHRP for Clinical Research, Director, HJF Component of MHRP, U.S. Military HIV Research Program, United States
Antonio Roldao, Senior Researcher, iBET – Instituto de Biologia Experimental e Tecnológica, Portugal
Dr Jerald Sadoff, Senior Advisor Vaccine Development, Janssen Infectious Diseases and Vaccines, United States
Michael Salter, R&D Facilitator, A.B. Agri, United Kingdom
Dr Adel Samson, Lead, Translational Cancer Immunotherapy Group, University of Leeds, United Kingdom
Dr Melanie Saville, Director Vaccine Development, CEPI, France
Dr Hanneke Schuitemaker, Vice President and Head of Viral Vaccine Discovery and Translational Medicine, Janssen, Netherlands
Dr Joerg (Jörg) Schwinde, Eppendorf AG, Germany
Dr Darin Seehafer, Clinical Scientist/Program Director, PRA Health Sciences, United States
Dr Ruud Segers, Executive Director, Clinical Research & Head Global Swine Biologicals R&D, MSD Animal Health, Netherlands
Dr Katherine Shives, R&D Scientist, Sartorius-Stedim-Biotech, United States
Ricardo Silva, Researcher, iBET – Instituto de Biologia Experimental e Tecnológica, Portugal
Bruno Speder, Head of Clinical Regulatory Affairs, SGS – Life Science Services, Belgium
Prof Daniel Speiser, Head of Clinical Tumour Biology and Immunotherapy Group, University of Lausanne, Switzerland
Julia Spencer, Executive Director, Global Vaccine Policy & Government Relations, MSD, United States
Dr Koert Stittelaar, Director Preclinical Services, Viroclinics Biosciences, Netherlands
Dr Christine Tait-Burkard, Assistant Professor, The Roslin Institute, United Kingdom
Dr Sybil Tasker, Chief Medical Officer, Altimmune, United States
Dr Mark Throsby, Chief Scientific Officer, Merus B.V., Netherlands
Dr Peter Timmerman, Chief Scientific Officer, Pepscan Therapeutics, Netherlands
Dr Lincoln Tubbs, Director, Food Animal Vaccines R&D, Elanco Animal Health, United States
Aernout Van Haarst, Director of Scientific Affairs, Celerion, United Kingdom
Dr Elly Van Riet, Head of Exploratory and Clinical Research, Intravacc, Netherlands
